Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three patients with cardiac tamponade caused by malignancy were treated by pericardiocentesis with intrapericardial OK-432 instillation. The underlying disease was adenocarcinoma of unknown origin, breast cancer and multiple myeloma. Under electrocardiographic monitoring, a polyethylene catheter with several side holes was inserted into the pericardial sac, and after a maximal volume of fluid was withdrawn, 5 KE of OK-432 diluted in 20 ml of saline was instilled through the catheter. All the patients who received intrapericardial OK-432 therapy obtained complete control of pericardial effusion for more than 30 days. The side effects were fever, chills and chest pain which were easily controlled by antipyretics.
 ...
PMID:Intrapericardial instillation of OK-432 for the management of malignant pericardial effusion: report of three cases. 272 48

From March, 1976 to June, 1983, 22 patients (10 males, 12 females) treated by maintenance hemodialysis were autopsied in our department. Primary diseases of the autopsied cases were chronic glomerulonephritis (12 cases), diabetes mellitus (three cases), hydronephrosis (three cases), systematic lupus erythematosus (two cases), myeloma kidney (one case) and atherosclerosing nephropathy (one case). Direct causes of death in maintenance hemodialysis patients were bleeding (six cases), uremia (three cases), infection (three cases), carcinoma (four cases), heart failure (two cases), myocardial infarction (one case), brain ischemia (one case), cardiac tamponade (one case) and unknown (one case).
 ...
PMID:Autopsy findings in maintenance hemodialysis patients. 653 69

We describe two patients who developed severe haemorrhagic complications. One manifested massive vaginal bleeding and the second haemopericardium with cardiac tamponade. In both cases histopathological examination showed subendothelial deposits of amyloid. Since other local and systemic causes of the haemorrhagic complications were excluded the bleeding was most probably due to amyloid angiopathy. Therefore, amyloid angiopathy should be considered in the differential diagnosis of bleeding in patients with amyloidosis associated with multiple myeloma.
 ...
PMID:Unusual bleeding manifestations of amyloidosis in patients with multiple myeloma. 773 13

Restrictive cardiomyopathy from amyloid deposition within the myocardium is a well-described complication of multiple myeloma; however, myelomatous involvement of pericardium with subsequent cardiac tamponade has rarely been described. Optimal treatment for malignant involvement of the pericardium by myeloma cells has yet to be established. The following description is of a patient with myocardial and pericardial manifestations of multiple myeloma. Treatment of the malignant pericardial effusion was implemented with intrapericardial administration of bleomycin. This therapy resulted in no recurrence of pericardial effusion at nine days follow-up. Despite the absence of detectable recurrent effusion, the patient died suddenly from causes felt unrelated to pericardial disease.
 ...
PMID:Multiple myeloma complicated by restrictive cardiomyopathy and cardiac tamponade. 844 98

Pericardial involvement and cardiac tamponade are rare complications of multiple myeloma (MM) and in most reported cases it has been diagnosed only at autopsy. Three cases of multiple myeloma with pericardial involvement seen at a single institution are described. The approach to the treatment is discussed and the literature on this rare complication of MM is briefly reviewed.
 ...
PMID:Multiple myeloma with pericardial involvement and cardiac tamponade: a report of three patients. 904 75

We report a patient with AL amyloidosis and chemo-resistant light-chain multiple myeloma who developed a progressive malignant pericardial effusion leading to cardiac tamponade. Despite pericardiocentesis and surgical intervention, the pericardial effusion failed to resolve. The administration of oral colchicine produced symptomatic relief within 5 days, with the resolution of pericardial effusion after 14 days of treatment. As the administration of colchicine is simple and the side-effect is usually minimal, further studies are warranted to establish the feasibility of using colchicine to treat malignant pericardial effusion.
 ...
PMID:Colchicine: an effective treatment for refractory malignant pericardial effusion. 1127 15

We report a case of right-sided heart failure associated with multiple myeloma. Amyloidosis was proven by rectal biopsy. In this case we were able to demonstrate myocardial disease by using tissue Doppler echocardiography, even in the presence of cardiac tamponade.
 ...
PMID:Discrimination between pericardial disease and myocardial disease using tissue Doppler imaging in a patient with right-sided heart failure and multiple myeloma. 1260 75

Multiple myeloma is a condition usually associated with lesions of the skeleton. However, under rare circumstances, the malignant plasma cells may infiltrate the pericardium, resulting in an effusion. If left untreated, the abnormal accumulation of pericardial fluid will result in cardiac tamponade, requiring drainage. The following report describes a multiple myeloma patient who developed secondary pericardial and pleural effusions, which were surgically drained via a pleuropericardial window.
 ...
PMID:Malignant pericardial effusion--an uncommon complication of multiple myeloma: case report. 1576 30

Multiple myeloma presents with various clinical manifestations depending on the mode and the extent of organ involvement. Pericardial involvement by myeloma and subsequent cardiac tamponade is extremely rare. We report on the case of a patient with multiple myeloma who presented with cardiac tamponade and was evaluated surgically with thoracotomy and minimal debulking pericardiectomy (fenestration).
 ...
PMID:Operative evaluation of cardiac tamponade in a patient with multiple myeloma. 1747 66

Cyclophosphamide is used for liver cancer, breast cancer and multiple myeloma, and the pretreatment of hematopoietic stem cell transplantation. A medium to high dose of cyclophosphamide is known to cause irreversible heart failure in some cases, and recently cardiac tamponade and pericarditis have been reported to occur when cyclophosphamide is administered for the pretreatment of hematopoietic stem cell transplantation. To test whether cyclophosphamide itself induces cellular toxicity, we investigated a toxic effect of cyclophosphamide, acrolein, a metabolite of cyclophosphamide, and doxorubicin, which is known to have cardiac toxicity, in the H9c2 cell line and the isolated Langendorff-perfused rat hearts. Cyclophosphamide itself did not have a toxic effect, whereas the toxicity of acrolein is 1, 000 times higher than that of doxorubicin in the H9c2 cell line. Acrolein, but not cyclophosphamide, reduced the left ventricular developed pressure and heart rate, and increased the left ventricular end diastolic pressure. These results suggest that the cardiac toxicity of cyclophosphamide may be caused by acrolein, one of its metabolites. Cyclophosphamide is known to cause hemorrhagic cystitis, and uromitexan was shown not to protect against the cardiac toxicity of cyclophosphamide. Development of new cardioprotective compounds is needed to administer CPA more safely.
 ...
PMID:[Analysis of cardiac toxicity caused by cyclophosphamide in the H9c2 cell line and isolated and perfused rat hearts]. 2041 25


1 2 Next >>